Solomon Moshkevich Sells 3,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $140.48, for a total transaction of $421,440.00. Following the completion of the sale, the insider now owns 141,782 shares in the company, valued at approximately $19,917,535.36. This trade represents a 2.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, March 17th, Solomon Moshkevich sold 1,026 shares of Natera stock. The stock was sold at an average price of $146.04, for a total value of $149,837.04.
• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The stock was sold at an average price of $143.29, for a total value of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Stock Performance

Shares of NTRA stock opened at $133.87 on Friday. The company has a market capitalization of $18.10 billion, a price-to-earnings ratio of -76.06 and a beta of 1.80. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock’s fifty day simple moving average is $156.81 and its 200-day simple moving average is $151.23.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Guggenheim lifted their price target on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. JPMorgan Chase & Co. raised their price target on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. The Goldman Sachs Group upped their price target on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Finally, Royal Bank of Canada started coverage on shares of Natera in a research note on Thursday, March 13th. They set an “outperform” rating and a $251.00 target price for the company. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. 111 Capital purchased a new position in shares of Natera during the 4th quarter valued at $397,000. Wealth Enhancement Advisory Services LLC boosted its position in Natera by 79.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 19,493 shares of the medical research company’s stock valued at $3,086,000 after purchasing an additional 8,635 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Natera in the fourth quarter valued at about $19,210,000. HWG Holdings LP increased its position in Natera by 173.0% in the 4th quarter. HWG Holdings LP now owns 40,739 shares of the medical research company’s stock worth $6,449,000 after purchasing an additional 25,819 shares during the last quarter. Finally, Polar Asset Management Partners Inc. raised its stake in shares of Natera by 1.6% during the 4th quarter. Polar Asset Management Partners Inc. now owns 96,105 shares of the medical research company’s stock worth $15,213,000 after purchasing an additional 1,500 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.